Margaret A. Tempero, M.D.

  • Chair, Clinical and Translational Cancer Research Peer Review Panel
    Director, UCSF Pancreas Center
    Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Research Focus

Dr. Tempero’s research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.


Creighton University, B.S., Medical Technology
University of Nebraska Medical Center, M.S., Clinical Pathology
University of Nebraska Medical Center, M.D., Medicine
University of Nebraska Medical Center, Residency, Internal Medicine
University of Nebraska Medical Center, Fellowship, Oncology

Other Experience

President, American Society of Clinical Oncology
Member, Board of Directors, American Society of Clinical Oncology
Organizer, Pancreas Cancer Think Tank
Co-Lead, NCI sponsored Progress Review Group on Pancreatic Cancer
Chair, NCCN Guidelines Panel on Pancreatic Cancer
Co-Chair, NCI Pancreas Task Force Tissue Acquisition Working Group
Co-Director, AACR/ASCO Methods in Clinical Cancer Research
Chair, NCI Clinical Oncology Study Section (CONC)
Member and Chair, NCI Board of Scientific Counselors
External Advisory Board, Pancreas SPORE, University of Alabama-Birmingham/University of Minnesota/Mayo Clinic
Scientific Advisory Board, Lustgarten Foundation; Pancreatic Cancer Action Network; The V Foundation; The Alberta Canada Cancer Board; EORTC
Oncology Drug Advisory Committee, FDA
Member, Clinical Advisory Board and Scientific Advisory Board, Raven Biotechnologies, Inc.
Member, Scientific Advisory Board at Ras Therapeutics, Inc.
Chairperson, Oncology Scientific Advisory Board at Rexahn Pharmaceuticals, Inc.
Member, Clinical Trial Advisory Board of Oxigene Inc.

Selected Honors

Doris & Donald Fisher Distinguished Professor in Clinical Cancer Research; University of California, San Francisco